US2890973A - Treating tobacco and cigarette paper - Google Patents
Treating tobacco and cigarette paper Download PDFInfo
- Publication number
- US2890973A US2890973A US716117A US71611758A US2890973A US 2890973 A US2890973 A US 2890973A US 716117 A US716117 A US 716117A US 71611758 A US71611758 A US 71611758A US 2890973 A US2890973 A US 2890973A
- Authority
- US
- United States
- Prior art keywords
- acid
- tobacco
- cozymase
- smoking
- yeast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000208125 Nicotiana Species 0.000 title description 34
- 235000002637 Nicotiana tabacum Nutrition 0.000 title description 34
- 235000019504 cigarettes Nutrition 0.000 title description 23
- 239000002253 acid Substances 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 230000000391 smoking effect Effects 0.000 claims description 16
- 230000003472 neutralizing effect Effects 0.000 claims description 15
- 230000001171 adenosinetriphosphoric effect Effects 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 7
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 38
- 229960003512 nicotinic acid Drugs 0.000 description 19
- 235000001968 nicotinic acid Nutrition 0.000 description 19
- 239000011664 nicotinic acid Substances 0.000 description 19
- 239000011269 tar Substances 0.000 description 19
- 239000000126 substance Substances 0.000 description 18
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 13
- PZFIDIJKTNDKOV-KWIZKVQNSA-J tetrasodium;[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate Chemical compound [Na+].[Na+].[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O PZFIDIJKTNDKOV-KWIZKVQNSA-J 0.000 description 10
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 8
- 239000000306 component Substances 0.000 description 8
- 238000002485 combustion reaction Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000779 smoke Substances 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 5
- 229930003270 Vitamin B Natural products 0.000 description 5
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 5
- 229950006790 adenosine phosphate Drugs 0.000 description 5
- 235000019156 vitamin B Nutrition 0.000 description 5
- 239000011720 vitamin B Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 3
- 229940048102 triphosphoric acid Drugs 0.000 description 3
- WQZBIMQFROXVSY-MCDZGGTQSA-N (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol;sodium Chemical compound [Na].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WQZBIMQFROXVSY-MCDZGGTQSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 235000019506 cigar Nutrition 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011273 tar residue Substances 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- D—TEXTILES; PAPER
- D21—PAPER-MAKING; PRODUCTION OF CELLULOSE
- D21H—PULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
- D21H5/00—Special paper or cardboard not otherwise provided for
- D21H5/12—Special paper or cardboard not otherwise provided for characterised by the use of special fibrous materials
- D21H5/14—Special paper or cardboard not otherwise provided for characterised by the use of special fibrous materials of cellulose fibres only
- D21H5/16—Tobacco or cigarette paper
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/20—Biochemical treatment
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
- A24B15/281—Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed
- A24B15/282—Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed by indirect addition of the chemical substances, e.g. in the wrapper, in the case
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
- A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
Definitions
- the smoke from the cigarette, cigar or the like should be admixed generally with at least one body or compound adapted to intervene into the cellular metabolism of human organism, more particularly into the cellular respiratory process.
- bodies or compounds are for instance vitamin B, vitamin PP (known as nicotinic acid or betapyridin-carboxylic acid), vitamin C, adenylic acid and pantothenic acid, as well as ferments and co-ferments.
- the ratio of betapyridincarboxylic acid to adenosinetriphosphoric acid should" range between about 10:1 and 10:4, it being understood.
- a typical composition according to this invention is as follows:
- Smoking was started when cutaneous temperatures were 7 stabilized, viz., when variations thereof were less than 0.1 C. Determination of the temperature was carried out every minute for a total time of at least fifteen minutes running from the start of smoking The vertical line 'A corresponding to 4.5 min. indicates when smoking was: i
- Curve B refers to the batch 1 (untreated cigarett'esL" It appears from this curve that in about six minutes after smoking was started cutaneous temperature was subjected to A C. decrease of 1.14 C., thereafter it beganincreasing andithen stabilized to its initial value after more than sixteen minutes from the moment the smoking' was if started.
- Curve C refers to cigarettes treated with nicotinic acid only (batch 2). i The maximum decrease in temperature was in this case 076 C. only and temperature stabilized to'its normal valueafter about sixteen minutes.
- Curve D refers to cigarettes of batch 6, that -is to cigarettesprepared according to one aspect of this inf vention. In this case, the maximum, decrease was 036 was interrupted, X Curve E refers to cigarettes of batch 15.
- Curve F refers to a cigarette from batch 10, which differs from batch 6 in that while in the latter 0.5 mg. sodium adenosinetriphosphate were employed, in the former 0.5 mg. adenylic acid were employed. Though curve F is more favourable for instance than curve C (nicotinic acid only), it will however be seen that it does not reach the advantage shown by curve D. This shows that adenylic acid cannot be looked upon as an equivalent of adenosinetriphosphoric acid (which evolves on decomposition of sodium adenosine triphosphate).
- this invention is based on a novel association of at least two components (nicotinic acid and adenosinetriphosphoric acid), preferably in combination with cozymase or cozymase II, in certain proportions to one another and .to tobacco such as to yield a synergetic action not obtainable with yeast only (compare batches 13-15 and curve E on the diagram), in any case superior to the action of nicotinic acid in association with adenylic acid (batch 9).
- the individual components should be separately available for duly proportioning thereof.
- a mixture of 0.5-30 parts by weight nicotinic acid (betapyridincarboxylic acid) and 0.5- parts by weight adenosinetriphosphoric acid (or sodium adenosine triphosphate) is separately prepared, adding, if needed, 0.1-1 part by weight cozymase I or II, this mixture being uniformly distributed over 1,000 parts by weight tobacco.
- nicotinic acid betapyridincarboxylic acid
- adenosinetriphosphoric acid or sodium adenosine triphosphate
- yeast which, as is well known, contains less than 0.05% cozymase I and similar irrelevant contents of nicotinic acid and adenosinetriphosphoric acid.
- Physical manipulation of the individual ingredients and tobacco for the purpose of thorough mixing, uniform distribution or impregnation is no problem per se and can be carried out in the usual manner in this branch, such as indicated by Steiner or Hicks.
- a neutralizing agent consisting of at least 0.5 mg. of betapyridincarboxylic acid, and at least 0.5 mg. of a compound selected from the group consisting of adenosine ltriphosphoric acid and sodium adenosine triphosphate per every gram of tobacco contained in the preparation.
- a neutralizing agent consisting of at least 0.5 mg. of betapyridincarboXylic acid, at least 0.5 mg. of a compound selected from the group consisting of adenosine triphosphoric acid and sodium adenosine triphosphate, and at least 0.1 mg. of an enzyme selected from the group consisting of cozymase I and cozymase II per every gram of the tobacco contained in the preparation.
- a neutralizing agent consisting of about 5 mg. betapyridincarboxylic acid, and about 0.5 mg. sodium adenosine triphosphate per every gram of the tobacco contained in the preparation.
- a neutralizing agent consisting of about 5 mg. betapyridincarboxylic acid, about 0.5 mg. sodium adenosine tr-iphosphate, and at least 0.1 mg. cozymase II per every gram of tobacco contained in the preparation.
- a neutralizing agent consisting of about 5 mg. betapyridincarboxylic acid, about 0.5 mg. adenosine triphosphoric acid, and at least 0.1 mg. cozymase II per every gram of tobacco contained in the preparation.
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Manufacture Of Tobacco Products (AREA)
Description
June 1959 G. FACHINI TREATING TOBACCO AND CIGARETTE PAPER Filed Feb. 19, 1958 United States Paten 2,890,973 TREATING TOBACCO AND CIGARETTE PAPER Giuseppe Fachini, Milan, Italy Application February 19, 1958, Serial No. 716,117 Claims priority, application Italy March 3, 1954 5 Claims. Cl. 131-47 This invention relates to tobacco preparations for smoking and aims generally to neutralise toxic and cancerogenicefiects of tobacco.
Attempts have been made for a long time to treat tobacco or cigarette paper with a view to neutralizing or at least reducing toxic elfects of smoke inspired by smokers. So, for instance U.S. Patent 1,842,266 to Calvin S. Hicks suggests to admix tobacco with a proportion of yeast (OBI-%). This prior proposal is based on the acknowledgment that the effects of smoke on human organism are the same as or similar to those produced by the deficiency of vitamin B, more particularly depression of growth, depression of the physiological system, autointoxication, loss of appetite, dyspepsia, intestinal stasis or stoppage, disruption of neuro-muscular control and general lowering of vitality and ability to ward 01f infection. Since, as is well known, yeast is a product relatively rich in vitamin B, Hicks exactly proposes to admix tobacco blend with yeast, so that vitamin B can be inspired by the smoker and absorbed by the organism for neutralizing the above toxic efiects.
A more recent work in this field is due to Pierre Steiner (French Patent No. 932,560, published on March 25, 1948). According to Steiner, the smoke from the cigarette, cigar or the like should be admixed generally with at least one body or compound adapted to intervene into the cellular metabolism of human organism, more particularly into the cellular respiratory process. These bodies or compounds are for instance vitamin B, vitamin PP (known as nicotinic acid or betapyridin-carboxylic acid), vitamin C, adenylic acid and pantothenic acid, as well as ferments and co-ferments.
In experiments, which have preceded my invention I ascertained that the discoveries by Hicks and Steiner actually involve improvements in reaction against smoke by the human organism, consisting more particularly in a smaller lowering of cutaneous temperature upon smoking a cigarette, as well as in more rapid restoring to normal temperature.
It should however be added now that, according to more recent scientific opinions, objectionable smoke ef fects are due prevailingly to tar substances generated on combustion of tobacco, said substances when inspired by the smoke being responsible not only for most of the above mentioned intoxication symptoms, but also above all, of some forms of cancer, such as lung cancer. Therefore in determining the useful efifects of neutralizing agents such as yeast, nicotinic acid etc. a fundamental importance should be attributed to the contents of tar substances in thesmoke from cigarettes which have been admixed with such agents. Unfortunately as will be explained in greater detail hereafter, neutralizing agents proposed heretofore are incapable of substantially and appreciably reducing said content. So, for instance, combustion of one gram tobacco of cigarettes known in Italy by the brand Nazionali yields about 0.047 gram of tar substances. Combustion of one gram of the same to- 10 mg. of brewers yeast yields about 0.041 gram of tar substances. These contents are further lowered when adding 100 mg. of yeast. However, in the latter case, the cigarettetaste is however fully altered, while the reduction in tar substance content does not reach even 20% with respect to the original value.
Nicotinic acid (betapyridincarboxylic acid) has been found more advantageous under this aspect as a proportion of 0.05% of said acid reduces the tar substances content to a value of about 0.036 gram per gram of tobacco and, when added in relatively high proportions (50 mg./=g.) which are not always cheap, said content is lowered down to 0.024 gram (about a half of the original content).
These results cannot be regarded as satisfactory both because they require an excessive proportion of neutral izing agents and-because a reduction down to 50% of the tar substances content can be reached even through suitable filters, which are considerably less expensive and do not alter the cigarette taste.
Now inconsiden'ng these results obtainable heretofore I conceived that better results could be reached if a neutralizing agent could be built .up comprising at least two components, one of which should exert a synergetic action inrespect of the other. It should be noted that this concept of the synergetic action is thoroughly novel in this field, inasmuch as, contrarily to the proposals by Steiner or Hicks, it is not based on the choice of one or other compound merely because it contains a vitamin or an enzyme, but involves a combination of at least two compounds Which, by acting jointly, yield immediate results (substantial reduction in tar substances content) beyond any expectation.
Startingfrom this idea I have found that the neutralizing efiect due. to betapyridincarboxylic acid becomes highly appreciable if this acid be accompanied by the adenosinetriphosphoricacid or a salt of the latter which, by decomposing, exactly yields adenosinetriphosphoric acid. Such salt could be more particularly sodium adenosinetriphosphate. Moreover, I further ascertained that further improved results are obtained by adding to the two abovementioned components (betapyridincarboxylic and adenosinetriphosphoric acid) a coenzyme selected from the group consisting of cozymase I and cozymase II.
This application is a continuation-in-part of my application Serial No. 491,545, filed March 1, 1955, now abandoned.
It should be noted at this stage that all these com ponents are to-be found in yeast which, however, also and prevailingly contains numerous further components have found it important for the relative proportions of baccosblend which has, however, beenadmixed with said componentsto be maintained above certain minimum values. A So,- for instance, for the synergetic action to develop fully and in order. to attain ,a maximum reduction in tar substances there should be to. each gramtobacco 05-30 mg. (0.054%) betapyridincarboxylic acid (nicotinic acid) and 0.5-5 mg. (0.040.5%) adenosinetriphosphoric acid or its abovementioned sodium salt possibly with at least 0.1-1 mg. (0.01-0.1%') cozymase I or cozymase II. Greater importance should be attributed to lower limits for, if desired, top limits can be exceeded which is, however, detrimental to thecigarette:
taste and economy, since proportions exceeding those indicated above do not lead to appreciable further improvements. Moreover, generally, the ratio of betapyridincarboxylic acid to adenosinetriphosphoric acid should" range between about 10:1 and 10:4, it being understood.
that in the presence of cozymase I or cozymase II the proportion of adenosinetriphosphoric acid should be displaced towards its lower limit.
A typical composition according to this invention is as follows:
Tobacco 1.0 g. Nicotinic acid mg. (0.5%) Sodium adenosinetriphosphate 0.5 mg. (0.05%)
the percentages being by weight and being referred to the tobacco quantity. i
The effects obtained by this invention can be looked upon as surprising in respect of the tar substances content and lowering of the cutaneous temperature during smoking and after smoking, as will be better explained hereafter. From tobacco composing the cigarettes of the brand Nazionali seventeen different batches were prepared, numbered 1 to 17 in the following table, of the composition given in the table. From each batch 100 cigarettes were manufactured, which were smoked in an apparatus comprising a mouthpiece connected with a suction pump through a number of Drechsel (bubbling) bottles followed by a Liebig cooler. Each Drechsel bottle contained 50 ml. chloroform which is known as an elective solvent for tar substances. With an apparatus prepared as above, a cigarette is inserted into the mouthpiece, suction by the pump is adjusted to be, as Will be ascertained from the extent of bubbling, rather moderate and uniform, the cigarette being then lit. Under these conditions the tar substances evolved on combustion of tobacco are absorbed by chloroform and any non-absorbed proportion are condensed in the Liebig cooler. Upon smoking synergetic action. It will therefore be obvious that use of yeast as neutralizing agent could be justified by its vitamin B content but is not connected in the least with the spirit and scope of this invention. So, for instance, yeast probably exerts on the human organism delayed actions, connected with its vitaminic contents as well as a certain action which somewhat reduces the usual lowering of the cutaneous'temperature, as will be explained in greater than preventive properties.
ined on separately considering batches 2 and 16. It is further pointed out that the result yieldedby batch 6 or 11 or 12 is undoubtedly surprising over the result yielded bybatches' such as 7 or 10 which lacked adenosinetri phosphoric acid, which is the chief synergetic agent acthe 100 cigarettes of one batch, the apparatus is disassembled, all its component parts are Washed with chloroform in order to collect any trace of tar substances, the whole chloroform containing the tar substances being evaporated on a boiling water bath. The tar residue is I weighed, the resulting weight being divided by the weight of the burnt tobacco. This yields the weight of tar sub-.
stances referred to one gram tobacco from the batch,
The same procedure was followed with further 16 batches, the results being as follows:
' Tar con- Batch No. Composition referred to 1 g. of tobacco tent per g. o tobacco G. not treated a 0. 04733 5 mg. nicotinic acid. 0.03587 50 mg. nicotinic acid... 0.02352 {5 mg. nicotinic acid 0 01321 0.5 mg. sodium adenosine triphosphate {5 mg. nicotinic acid... 0 01296 2 mg. sodium adenosine triphospha 5 mg. nicotinic acid 0.5 mg. sodium adenosine triphosphate 0.01271 1 mg. Oozymase 0. 02783 0. 01063 0. 02662 0.02317 {0.5 mg. sodium aderio me 0.01295 1 mg. Cozymase I 5 mg. nicotinic acid 12 0.5 mg. adencsine triphosphoric acid 0. 01214 The above table (batches 1, 13, 14, 15) shows first of all that the admixture of yeast, even in considerable proportions, leaves the tar substances content practically unaffected. This may be explained by the fact that nicotinic acid, adenosinetriphosphorie acid and cozymase are found in yeast in negligible proportions for practical use and are probably not in a condition suitable to promote a cordingto this invention.
The best results were yielded by batches 5, 6, 11 and 12 f in which the tar substances content was reduced to about 0.012 g. per grain of tobacco through an addition of neutralizing agents which does not exceed 7 mg. The result yielded by batch 8 can be looked upon as exceptional, l
but has beeniobtained through larger proportions of neufore unacceptable.
Reference will hereafter be made to the accompanying 7 drawing, showing adiagram on which the abscissae give in minutes and the ordinates the drop A C. intemperature. The curves plotted on this diagramweredetermined by experiments on human subjects, each curve showing the average of the results of 44 tests.
Each time a cigarette was smoked by a subject in four employed for measuring cutaneous temperature.
Smoking was started when cutaneous temperatures were 7 stabilized, viz., when variations thereof were less than 0.1 C. Determination of the temperature was carried out every minute for a total time of at least fifteen minutes running from the start of smoking The vertical line 'A corresponding to 4.5 min. indicates when smoking was: i
interrupted.
' Curve B refers to the batch 1 (untreated cigarett'esL" It appears from this curve that in about six minutes after smoking was started cutaneous temperature was subjected to A C. decrease of 1.14 C., thereafter it beganincreasing andithen stabilized to its initial value after more than sixteen minutes from the moment the smoking' was if started.
Curve C refers to cigarettes treated with nicotinic acid only (batch 2). i The maximum decrease in temperature was in this case 076 C. only and temperature stabilized to'its normal valueafter about sixteen minutes.
Curve D refers to cigarettes of batch 6, that -is to cigarettesprepared according to one aspect of this inf vention. In this case, the maximum, decrease was 036 was interrupted, X Curve E refers to cigarettes of batch 15.
. In comparisonwith curve B, this curve E denotes. a certain improvement in the sense that decrease in tem-' perature was 0.81 C. only (instead of 1.'14 C.) and temperatureistabilized more quickly.. However,'the subjects all complained about astrange taste of the ciga .5 fettes which, on the other hand, was not at all surprising, since each cigarette contained 10% yeast.
Curve F refers to a cigarette from batch 10, which differs from batch 6 in that while in the latter 0.5 mg. sodium adenosinetriphosphate were employed, in the former 0.5 mg. adenylic acid were employed. Though curve F is more favourable for instance than curve C (nicotinic acid only), it will however be seen that it does not reach the advantage shown by curve D. This shows that adenylic acid cannot be looked upon as an equivalent of adenosinetriphosphoric acid (which evolves on decomposition of sodium adenosine triphosphate).
Considering the preceding description, it is believed that experts the branch are now in a condition to fully appreciate the spirit and scope of this invention, as well as the diiferences between this invention and teachings of the prior art. More particularly, as shown by the preceding table and diagram on the accompanying drawing, this invention is based on a novel association of at least two components (nicotinic acid and adenosinetriphosphoric acid), preferably in combination with cozymase or cozymase II, in certain proportions to one another and .to tobacco such as to yield a synergetic action not obtainable with yeast only (compare batches 13-15 and curve E on the diagram), in any case superior to the action of nicotinic acid in association with adenylic acid (batch 9). This leads to believe that, while adenylic acid chiefly acts on the subject and affects combustion by a small extent only, as distinct therefrom, adenosinetriphosphoric acid besides positively affecting the subject moreover gives rise to decomposition products which co act with nicotinic acid in strongly afiecting in a negative sense building up of tar substances, thereby preventing at the start possible eifects on the human organism.
It will be moreover understood that, in order to carry out the invention, the individual components should be separately available for duly proportioning thereof. Generally, a mixture of 0.5-30 parts by weight nicotinic acid (betapyridincarboxylic acid) and 0.5- parts by weight adenosinetriphosphoric acid (or sodium adenosine triphosphate) is separately prepared, adding, if needed, 0.1-1 part by weight cozymase I or II, this mixture being uniformly distributed over 1,000 parts by weight tobacco. However, it is pointed out that, since the proportion of the agents according to this invention with respect to tobacco is generally significantly small, these agents can even be jointly incorporated for instance in cigarette 6. paper or any component of the cigarette or cigar taking part in combustion. This would not be possible with yeast which, as is well known, contains less than 0.05% cozymase I and similar irrelevant contents of nicotinic acid and adenosinetriphosphoric acid. Physical manipulation of the individual ingredients and tobacco for the purpose of thorough mixing, uniform distribution or impregnation is no problem per se and can be carried out in the usual manner in this branch, such as indicated by Steiner or Hicks.
What I claim is:
1. In a smoking preparation of tobacco, a neutralizing agent consisting of at least 0.5 mg. of betapyridincarboxylic acid, and at least 0.5 mg. of a compound selected from the group consisting of adenosine ltriphosphoric acid and sodium adenosine triphosphate per every gram of tobacco contained in the preparation.
2. In a smoking preparation of tobacco, a neutralizing agent consisting of at least 0.5 mg. of betapyridincarboXylic acid, at least 0.5 mg. of a compound selected from the group consisting of adenosine triphosphoric acid and sodium adenosine triphosphate, and at least 0.1 mg. of an enzyme selected from the group consisting of cozymase I and cozymase II per every gram of the tobacco contained in the preparation.
3. In a smoking preparation of tobacco, a neutralizing agent consisting of about 5 mg. betapyridincarboxylic acid, and about 0.5 mg. sodium adenosine triphosphate per every gram of the tobacco contained in the preparation.
4. In a smoking preparation of tobacco, a neutralizing agent consisting of about 5 mg. betapyridincarboxylic acid, about 0.5 mg. sodium adenosine tr-iphosphate, and at least 0.1 mg. cozymase II per every gram of tobacco contained in the preparation.
5. In a smoking preparation of tobacco, a neutralizing agent consisting of about 5 mg. betapyridincarboxylic acid, about 0.5 mg. adenosine triphosphoric acid, and at least 0.1 mg. cozymase II per every gram of tobacco contained in the preparation.
References Cited in the file of this patent FOREIGN PATENTS
Claims (1)
1. IN A SMOKING PREPARATION OF TOBACCO, A NEUTRALIZING AGENT CONSISTING OF AT LEAST 0.5 MG. OF BETAPYRIDINCARBOXYLIC ACID, AND AT LEAST 0.5 MG. OF A COMPOUND SELECTED FROM THE GROUP CONSISTING OF ADENOSINE TRIPHOSPHORIC
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2890973X | 1954-03-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US2890973A true US2890973A (en) | 1959-06-16 |
Family
ID=11436212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US716117A Expired - Lifetime US2890973A (en) | 1954-03-03 | 1958-02-19 | Treating tobacco and cigarette paper |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US2890973A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3043723A (en) * | 1959-09-17 | 1962-07-10 | Gen Cigar Co | Process and product utilizing tobacco stems |
| US3339558A (en) * | 1966-10-28 | 1967-09-05 | Haskett Barry F | Smoking article and filter therefor containing vitamin a |
| US3844294A (en) * | 1970-03-23 | 1974-10-29 | Ici Ltd | Tobacco substitute smoking mixture |
| EP0116085A4 (en) * | 1982-08-05 | 1984-11-16 | William Alvin Carter | INTERFERON AND INTERFERON INDUCERS COMBINED WITH TOBACCO PRODUCTS. |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR932560A (en) * | 1944-06-20 | 1948-03-25 | Device usable in the consumption of tobacco by combustion | |
| FR932561A (en) * | 1944-05-31 | 1948-03-25 | Tobacco |
-
1958
- 1958-02-19 US US716117A patent/US2890973A/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR932561A (en) * | 1944-05-31 | 1948-03-25 | Tobacco | |
| FR932560A (en) * | 1944-06-20 | 1948-03-25 | Device usable in the consumption of tobacco by combustion |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3043723A (en) * | 1959-09-17 | 1962-07-10 | Gen Cigar Co | Process and product utilizing tobacco stems |
| US3339558A (en) * | 1966-10-28 | 1967-09-05 | Haskett Barry F | Smoking article and filter therefor containing vitamin a |
| US3844294A (en) * | 1970-03-23 | 1974-10-29 | Ici Ltd | Tobacco substitute smoking mixture |
| EP0116085A4 (en) * | 1982-08-05 | 1984-11-16 | William Alvin Carter | INTERFERON AND INTERFERON INDUCERS COMBINED WITH TOBACCO PRODUCTS. |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3385303A (en) | Reconstituted tobacco product | |
| US4694842A (en) | Tea-containing tobacco | |
| US4489739A (en) | Smokable tobacco composition and method of making | |
| US5326563A (en) | Nicotine compositions | |
| JP3145702B2 (en) | Smoking composition | |
| US3722516A (en) | Smoking tobacco product and method of making the same | |
| CN110810887A (en) | Processing method of burley tobacco | |
| CN103445288A (en) | Processing method for increasing usability of burley tobacco | |
| WO1987006104A1 (en) | Improvements in and relating to tobacco products | |
| DE2356706A1 (en) | SMOKE MIXTURES | |
| US2890973A (en) | Treating tobacco and cigarette paper | |
| US2171986A (en) | Paper and paper making | |
| CA2803587A1 (en) | Cellulosic material such as tobacco comprising one or more smoke diluents | |
| US1842266A (en) | Toracco mixture | |
| CN111602838A (en) | Feed liquid for increasing scorched and sweet aroma of tobacco leaves and method for treating tobacco leaves | |
| KR900007855B1 (en) | Process for making cigarettes from leaf of eucommia ulmoides oliver | |
| US3085581A (en) | Process of treating tobacco and the resultant product | |
| US2460285A (en) | Tobacco products and method of making them | |
| US4600026A (en) | Tobacco composition with bluish dogbane and a process for the preparation thereof | |
| Gala et al. | Influence of neurohumors on anterior pituitary lactogen production in vitro. | |
| CN1100610A (en) | Cigarette made of tobacco substitutes | |
| US3251368A (en) | Method of treating tobacco to improve its smoking properties and ash colour | |
| US2331830A (en) | Tobacco | |
| WO1999020131A1 (en) | A cigarette of ginkgo leaves | |
| US729218A (en) | Process of improving tobacco. |